178 related articles for article (PubMed ID: 37060576)
1. Emerging drugs in the treatment of chronic cough.
Brister D; Wahab M; Rashad M; Diab N; Kolb M; Satia I
Expert Opin Emerg Drugs; 2023 Dec; 28(2):67-77. PubMed ID: 37060576
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported experiences with refractory or unexplained chronic cough: a qualitative analysis.
Bali V; Schelfhout J; Sher MR; Tripathi Peters A; Patel GB; Mayorga M; Goss D; Romano CD
Ther Adv Respir Dis; 2024; 18():17534666241236025. PubMed ID: 38501735
[TBL] [Abstract][Full Text] [Related]
3. Determining What Represents Value in the Treatment of Refractory or Unexplained Chronic Cough from the Perspective of Key Stakeholders in Spain Using Multi-Criteria Decision Analysis.
Domingo C; Fernandez M; Garin N; Milara J; Moran I; Muerza I; Pacheco A; Teruel C; Bentley R; Subiran R; Gil A
Appl Health Econ Health Policy; 2023 Jan; 21(1):119-130. PubMed ID: 36319945
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough.
Mazzone SB; McGarvey L
Clin Pharmacol Ther; 2021 Mar; 109(3):619-636. PubMed ID: 32748976
[TBL] [Abstract][Full Text] [Related]
5. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
Muccino D; Green S
Pulm Pharmacol Ther; 2019 Jun; 56():75-78. PubMed ID: 30880151
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and Management of Patients with Refractory or Unexplained Chronic Cough in Outpatient Hospital Clinics in Spain: A Retrospective Multicenter Study.
Dávila I; Puente L; Quirce S; Arismendi E; Díaz-Palacios M; Pereira-Vega A; de Diego A; Rodriguez-Hermosa JL; Cea-Calvo L; Sánchez-Jareño M; López-Cotarelo P; Domingo C
Lung; 2023 Jun; 201(3):275-286. PubMed ID: 37160771
[TBL] [Abstract][Full Text] [Related]
7. Understanding physician's knowledge and perception of chronic cough in Switzerland.
Leuppi JD; Guggisberg P; Koch D; Favre-Bulle A; Fabiani M; Heinz S; Zeller A
Curr Med Res Opin; 2022 Aug; 38(8):1459-1466. PubMed ID: 35369836
[TBL] [Abstract][Full Text] [Related]
8. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough.
McGarvey L; Smith JA; Morice A; Birring SS; Chung KF; Dicpinigaitis PV; Niimi A; Benninger MS; Sher M; Matsunaga Y; Miyazaki S; Machida M; Ishihara H; Mahmood A; Gomez JC
Lung; 2023 Feb; 201(1):25-35. PubMed ID: 36512069
[TBL] [Abstract][Full Text] [Related]
9. A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory or unexplained chronic cough.
Niimi A; Sagara H; Kikuchi M; Arano I; Sato A; Shirakawa M; La Rosa C; Muccino D
Allergol Int; 2022 Oct; 71(4):498-504. PubMed ID: 35752582
[TBL] [Abstract][Full Text] [Related]
10. Antitussive efficacy of the current treatment protocol for refractory chronic cough: our real-world experience in a retrospective cohort study.
Zhang M; Morice AH; Si F; Zhang L; Chen Q; Wang S; Zhu Y; Xu X; Yu L; Qiu Z
Ther Adv Respir Dis; 2023; 17():17534666231167716. PubMed ID: 37078383
[TBL] [Abstract][Full Text] [Related]
11. The Therapeutic Landscape in Chronic Cough.
Smith JA
Lung; 2024 Feb; 202(1):5-16. PubMed ID: 38127133
[TBL] [Abstract][Full Text] [Related]
12. [Chronic cough].
Kardos P
Pneumologie; 2023 Aug; 77(8):574-585. PubMed ID: 37619576
[TBL] [Abstract][Full Text] [Related]
13. Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.
Smith JA; Birring SS; Dicpinigaitis PV; McGarvey LP; Morice AH; Pavord ID; Satia I; Green S; Iskold B; La Rosa C; Li Q; Martin Nguyen A; Schelfhout J; Muccino D
Lung; 2022 Aug; 200(4):423-429. PubMed ID: 35895098
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of P2X3 receptor antagonist for the treatment of refractory or unexplained chronic cough: A systematic review and meta-analysis of 11 randomized controlled trials.
Ramadan A; El-Samahy M; Elrosasy A; Al-Tawil M; Abdelaziz A; Soliman MA; Abouzid M
Pulm Pharmacol Ther; 2023 Dec; 83():102252. PubMed ID: 37678663
[TBL] [Abstract][Full Text] [Related]
15. ATP, an attractive target for the treatment of refractory chronic cough.
Zhang M; Sykes DL; Sadofsky LR; Morice AH
Purinergic Signal; 2022 Sep; 18(3):289-305. PubMed ID: 35727480
[TBL] [Abstract][Full Text] [Related]
16. A register-based study: cough - a frequent phenomenon in the adult population.
Backer V; Porsborg A; Hansen V; Skjold T; Schmid JM; Kehlet M; Torp-Pedersen C; Aasbjerg K
BMC Pulm Med; 2022 Nov; 22(1):426. PubMed ID: 36401236
[TBL] [Abstract][Full Text] [Related]
17. Chronic cough: new insights and future prospects.
Morice A; Dicpinigaitis P; McGarvey L; Birring SS
Eur Respir Rev; 2021 Dec; 30(162):. PubMed ID: 34853095
[TBL] [Abstract][Full Text] [Related]
18. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
Garceau D; Chauret N
Pulm Pharmacol Ther; 2019 Jun; 56():56-62. PubMed ID: 30902655
[TBL] [Abstract][Full Text] [Related]
19. Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough.
Dicpinigaitis PV; Birring SS; Blaiss M; McGarvey LP; Morice AH; Pavord ID; Satia I; Smith JA; La Rosa C; Li Q; Nguyen AM; Schelfhout J; Tzontcheva A; Muccino D
Ann Allergy Asthma Immunol; 2023 Jan; 130(1):60-66. PubMed ID: 35569802
[TBL] [Abstract][Full Text] [Related]
20. An update and systematic review on drug therapies for the treatment of refractory chronic cough.
Ryan NM; Vertigan AE; Birring SS
Expert Opin Pharmacother; 2018 May; 19(7):687-711. PubMed ID: 29658795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
